Annual Information Update

RNS Number:4098A
Celsis International PLC
18 July 2007



                         CELSIS INTERNATIONAL PLC
                  ("Celsis", "the Company" or "the Group")

                        ANNUAL INFORMATION UPDATE


18 July 2007: Celsis International plc, the life sciences products and
laboratory services company, is pleased to provide an annual information update,
in accordance with the requirements of the Prospectus Rule 5.2.  This update
refers to information that has been published or made available by the Company
to the public over the twelve months preceding this announcement.  To avoid a
statement of unnecessary length information is referred to in this update rather
than included in full.

In accordance with Rule 5.2.7 of the Prospectus Rules, the information referred
to in this update was up to date at the time the information was published but
some information may now be out of date.  This annual information update does
not constitute an offer of securities addressed to any person and should not be
relied on by any person.

1. Announcements made via the Regulatory News Service ("RNS"), a Regulatory
Information Service ("RIS").

Date of Publication            Regulatory Headline

6 June 2006                    Notice of results
14 June 2006                   Final results
14 June 2006                   Acquisition
16 June 2006                   Doc re. acquisition
7 July 2006                    Annual report and accounts
7 July 2006                    Annual information update
11 July 2006                   EGM statement
26 July 2006                   AGM statement
26 July 2006                   Result of AGM
31 July 2006                   Share options
1 August 2006                  Holding in company
30 August 2006                 Holding in company BARC
11 September 2006              Holding in company BARC
19 September 2006              Goodwill tax benefit on acquisition of IVT
28 September 2006              Preclose trading update
25 October 2006                Notice of results
2 November 2006                Holding in company BARC
8 November 2006                Interim results
17 November 2006               Director/pdmr shareholding
22 November 2006               Holding in company BARC
15 December 2006               Holding in company BARC
24 January 2007                Treasury stock
1 February 2007                Total voting rights
5 February 2007                Holding in company BARC
6 March 2007                   Holding in company
9 March 2007                   Holding in company
16 March 2007                  Holding in company BARC
20 March 2007                  Holding in company HBOS
28 March 2007                  Trading update
19 April 2007                  Holding in company HBOS
15 May 2007                    Appointments
16 May 2007                    Notice of results
20 June 2007                   Final results
5 July 2007                    Holding in company BARC
9 July 2007                    Annual report and accounts

Copies of all announcements can be obtained from the Regulatory News Service of 
the London Stock Exchange.


2. Documents filed at Companies House

The documents listed below were filed with the Registrar of Companies in England
and Wales on or around the dates indicated.  Copies of these documents can be
obtained from Companies House.

Date               Document type     Description

26 June 2006       363               Annual Return
18 July 2006       287               Change in situation or address of registered office
27 July 2006       AA                Report and Accounts
2 July 2007        288a              Appointment of new Non Executive Director, Peter Jensen
2 July 2007        288a              Appointment of new Non Executive Director Nicholas Badman


3. Documents sent to Shareholders

The documents listed below have been despatched by the Company to holders of its
securities on or around the following dates.

Date                              Description

5 July 2007                       2007 Annual Report and Accounts
5 July 2007                       Notice of Annual General Meeting
28 November 2006                  2006 Interim Report


4. Documents submitted to the UK Listing Authority

Copies of the following documents have been submitted to the UK Listing
Authority for inspection at their Document Viewing Facility on or around the
following dates and can be obtained from the Company Secretary, Celsis
International plc, 1010 Cambourne Business Park, Cambourne, Cambridge, CB23 6DP.

Date                         Description

5 July 2007                  2007 Annual Report and Accounts
5 July 2007                  Notice of Annual General Meeting
28 November 2006             2006 Interim Report


Enquiries:
Celsis International plc                                      Tel: [phone]
Christian Madrolle, Company Secretary
Jenny Parsons, Corporate Communications
Financial Dynamics                                            Tel: [phone]

Ben Atwell
David Yates



Notes to editors

Celsis International plc

Celsis International plc is a world leading provider of innovative life science
products and laboratory services to the pharmaceutical, biopharmaceutical, and
consumer products industries through its three business areas; rapid detection,
analytical and drug development services and ADME-Tox in vitro technologies.
The company is listed on the London Stock Exchange (CEL.L).

Each division of Celsis International plc has the capacity to deliver
substantial time and cost savings to its customers, in addition to ensuring
product quality and safety for consumers.  Using proprietary technology, the
Celsis Rapid Detection division provides diagnostic systems for the rapid
detection of contamination.  These systems provide significant economic value by
reducing the time it takes to test and release raw materials, in process and
finished goods to market.  Celsis Analytical Services division provides cost
effective outsourced laboratory testing services to pharmaceutical and
biopharmaceutical companies.  Its comprehensive service offerings include a full
spectrum of laboratory services from drug development and discovery to
analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (Celsis IVT) supplies in vitro testing products to
the pharmaceutical and biotechnology industries.  IVT's in vitro products screen
drug compounds early in the discovery process, thereby reducing the time and
cost of drug development.

Further information can be found on its website at www.celsis.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AIUDDLFFDDBBBBX